Loading...
Loading...
Browse all stories on DeepNewz
VisitWill lenacapavir receive regulatory approval for HIV prevention in Uganda by the end of 2024?
Yes • 50%
No • 50%
Official announcements from the Uganda National Drug Authority (NDA)
Twice-Yearly Lenacapavir Injection 100% Effective in Preventing HIV Infections in Women in South Africa and Uganda
Jul 24, 2024, 05:02 PM
A new study published in the New England Journal of Medicine has shown that twice-yearly subcutaneous injections of lenacapavir are 100% effective in preventing HIV infections among women in South Africa and Uganda. The PURPOSE 1 randomized, controlled trial found that lenacapavir outperformed the daily oral emtricitabine–tenofovir disoproxil fumarate (PrEP) regimen, which has faced issues with low adherence. There were zero infections among the young women and girls who received the lenacapavir shots, compared to a 2% infection rate for those taking daily pills. Experts have described the results as 'stunning,' highlighting the potential of lenacapavir to revolutionize HIV prevention. The trial results were so compelling that researchers decided to stop the controlled test early.
View original story
Yes • 50%
No • 50%
Yes • 50%
No • 50%
11-15 countries • 25%
More than 15 countries • 25%
0-5 countries • 25%
6-10 countries • 25%
Lenacapavir adoption rate is 50% to 75% • 25%
Lenacapavir adoption rate is less than 25% • 25%
Lenacapavir adoption rate is more than 75% • 25%
Lenacapavir adoption rate is 25% to 50% • 25%